Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Castleman's disease, an atypical lymphoproliferative disorder, can be classified into 2 types: hyaline-vascular and plasma cell types according to the histologic features of the affected lymph nodes. The plasma cell type is frequently associated with systemic manifestations and is often refractory to systemic therapy including corticosteroids and chemotherapy, particularly in multicentric form. Dysregulated overproduction of interleukin-6 (IL-6) from affected lymph nodes is thought to be responsible for the systemic manifestations of this disease. Therefore, interference with IL-6 signal transduction may constitute a new therapeutic strategy for this disease. We used humanized anti-IL-6 receptor antibody (rhPM-1) to treat 7 patients with multicentric plasma cell or mixed type Castleman's disease. All patients had systemic manifestations including secondary amyloidosis in 3. With the approval of our institution's ethics committee and the consent of the patients, they were treated with 50 to 100 mg rhPM-1 either once or twice weekly. Immediately after administration of rhPM-1, fever and fatigue disappeared, and anemia as well as serum levels of C-reactive protein (CRP), fibrinogen, and albumin started to improve. After 3 months of treatment, hypergammaglobulinemia and lymphadenopathy were remarkably alleviated, as were renal function abnormalities in patients with amyloidosis. Treatment was well tolerated with only transient leukopenia. Histopathologic examination revealed reduced follicular hyperplasia and vascularity after rhPM-1 treatment. The pathophysiologic significance of IL-6 in Castleman's disease was thus confirmed, and blockade of the IL-6 signal by rhPM-1 is thought to have potential as a new therapy based on the pathophysiologic mechanism of multicentric Castleman's disease. (Blood. 2000;95:56-61)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994) · Science · doi:10.1126/science.7997879 · Cited by 5,654
Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M., Clauvel, J., Raphael, M., Degos, L., et al. (1995) · Blood · doi:10.1182/blood.v86.4.1276.bloodjournal8641276 · Cited by 2,157
Kishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Self-citationLocalized mediastinal lymph-node hyperplasia resembling thymoma
Castleman, B., Iverson, L., & Menendez, V. P. (1956) · Cancer · doi:10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4 · Cited by 1,621
Keller, A. R., Hochholzer, L., & Castleman, B. (1972) · Cancer · doi:10.1002/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-# · Cited by 1,355
Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,039
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928
Self-citationMolecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV
Moore, P. S., Boshoff, C., Weiss, R. A., & Chang, Y. (1996) · Science · doi:10.1126/science.274.5293.1739 · Cited by 904
Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells
Rincón, M., Anguita, J., Nakamura, T., Fikrig, E., & Flavell, R. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.461 · Cited by 810
AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.
Miles, S. A., Rezai, A. R., Salazar-González, J. F., Vander Meyden, M., Stevens, R. H., Logan, D. M., Mitsuyasu, R. T., Taga, T., Hirano, T., & Kishimoto, T. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4068 · Cited by 475
Self-citationMurine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Klein, B., Wijdenes, J., Zhang, X., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.1198 · Cited by 418
Nicholas, J., Ruvolo, V. R., Burns, W. H., Sandford, G., Wan, X., Ciufo, D., Hendrickson, S. B., Guo, H.-G., Hayward, G. S., & Reixz, M. S. (1997) · Nature Medicine · doi:10.1038/nm0397-287 · Cited by 389
Frizzera, G., Peterson, B. A., Bayrd, E. D., & Goldman, A. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.9.1202 · Cited by 380
Beck, J. T., Hsu, S.-M., Wijdenes, J., Bataille, R., Klein, B., Vesole, D., Hayden, K., Jagannath, S., & Barlogie, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300904 · Cited by 322
Induction of IL-6 (B cell stimulatory factor-2/IFN-beta 2) production by HIV.
Nakajima, K., Martínez-Maza, O., Hirano, T., Breen, E. C., Nishanian, P. G., Salazar-Gonzalez, J. F., Fahey, J. L., & Kishimoto, T. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.2.531 · Cited by 304
Self-citationReshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato, K., Tsuchiya, M., Saldanha, J. W., Koishihara, Y., Ohsugi, Y., Kishimoto, T., & Bendig, M. M. (1993) · PubMed · Cited by 290
Self-citationGessain, A., Sudaka, A., Briere, J., Fouchard, N., Nicola, M., Rio, B., Arborio, M., Troussard, X., Audouin, J., & Diebold, J. (1996) · Blood · doi:10.1182/blood.v87.1.414.414 · Cited by 167
A possible autocrine role for interleukin-6 in two lymphoma cell lines
Yee, C., Biondi, A., Wang, X., Iscove, N., de Sousa, J., Aarden, L., Wong, G., Clark, S., Messner, H., & Minden, M. (1989) · Blood · doi:10.1182/blood.v74.2.798.798 · Cited by 159
Lovat, L. B., Persey, M. R., Madhoo, S., et al. (1998) · Gut · doi:10.1136/gut.42.5.727 · Cited by 133
Nishimoto, N., Ogata, A., Shima, Y., Tani, Y., Ogawa, H., Nakagawa, M., Sugiyama, H., Yoshizaki, K., & Kishimoto, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1343 · Cited by 124
Self-citationRapid and sensitive chemiluminescent enzyme immunoassay for measuring tumor markers
Nishizono, I., Iida, S., Suzuki, N., Kawada, H., Murakami, H., Ashihara, Y., & Okada, M. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.9.1639 · Cited by 116
Screpanti, I., Musiani, P., Bellavia, D., Cappelletti, M., Aiello, F. B., Maroder, M., Frati, L., Modesti, A., Gulino, A., & Poli, V (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.4.1561 · Cited by 69
Cited by
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
IL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
INTERLEUKIN-6: From Basic Science to Medicine—40 Years in Immunology
Kishimoto, T. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115806 · Cited by 1,024
Self-citationIL-6/IL-6 receptor system and its role in physiological and pathological conditions
Mihara, M., Hashizume, M., Yoshida, H., Suzuki, M., & Shiina, M. (2012) · Clinical Science · doi:10.1042/cs20110340 · Cited by 895
Metadata
- Authors
- Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., & Yoshizaki, K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-01-01
- Volume
- 95
- Issue
- 1
- Pages
- 56-61
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W4234924147
- Cited by
- 441
- References
- 22
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.